Skip to main content
Acurx Pharmaceuticals, Inc. logo

Acurx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ACXP ISIN · US00510M1045 LEI · 5493006KI0IEUHE1UK56 US Manufacturing
Open in API
Filings indexed 211 across all filing types
Latest filing 2026-05-12 Share Issue/Capital Cha…
Country US United States of America
Listing US ACXP

About Acurx Pharmaceuticals, Inc.

https://www.acurxpharma.com/

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics. The company's therapeutic candidates are designed to treat infections caused by bacteria designated as priority pathogens by organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Acurx's approach involves developing antibiotics that inhibit a novel molecular target previously unexploited in medical research. A primary focus of its clinical development is the treatment of Clostridioides difficile Infection (CDI).

Recent filings

Filing Released Lang Actions
424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
Share Issue/Capital Change Classification · 78% confidence The document is a prospectus filed under SEC Rule 424(b)(3) to register and facilitate the resale of up to 1,300,000 shares of common stock by an existing selling stockholder. It details the terms of the resale offering, the registration statement, and capital structure changes (including reverse stock split and shares registered for resale). This aligns with a share issue/capital change filing rather than an earnings release, management discussion, or proxy statement.
2026-05-12 English
424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
Regulatory Filings Classification · 84% confidence The document is a SEC prospectus filed pursuant to Rule 424(b)(3) (Form 424B3) serving as a registration prospectus for the resale of existing shares by selling stockholders. It is not an annual or interim report, earnings release, proxy statement, or other specific category. As there is no dedicated “Prospectus” category in the taxonomy, and the document is a regulatory filing with the SEC, it falls into the Regulatory Filings (RNS) fallback category.
2026-05-12 English
S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
Capital/Financing Update Classification · 75% confidence The document is a Form S-1 registration statement and preliminary prospectus for Acurx Pharmaceuticals, Inc. to register and offer shares of common stock related to a financing (registered direct offering, exercise of warrants, resale of shares). This is a detailed securities offering/prospectus, which falls under updates on fundraising or capital structure changes rather than an annual or interim report, management changes, proxy materials, etc. Therefore, it is classified as a Capital/Financing Update.
2026-05-04 English
8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC by Acurx Pharmaceuticals, Inc. dated April 15, 2026. It reports the entry into a material definitive agreement related to a securities purchase agreement for a registered direct offering and a concurrent private placement of warrants. The document details the terms of the offering, the parties involved, and related agreements. It includes exhibits such as the purchase agreement, warrants, legal opinion, and a press release announcing the pricing of the offering. The content focuses on financing activities and capital raising, specifically the issuance and sale of securities and warrants. There are no financial statements or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy, governance, or management report. The primary subject is the capital raising transaction and related agreements, which fits the category of Capital/Financing Update (CAP). The document length is over 11,000 characters, indicating it is the full report, not just an announcement of a report publication. Therefore, the appropriate classification is CAP with high confidence.
2026-04-16 English
424B5 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering, specifically detailing the terms of a common stock and pre-funded warrants offering. It includes offering prices, placement agent fees, and legal disclaimers. The document is a registration statement supplement and not a financial report, earnings release, or management discussion. It is a detailed disclosure document for a capital raising transaction, consistent with a Capital/Financing Update. It is not an announcement of a report publication, nor a regulatory filing in the fallback sense, but a primary offering document. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-04-16 English
424B3 Filing
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of common stock by a selling stockholder. It includes detailed information about the offering, the selling stockholder, the use of proceeds, dilution, market for common stock, and legal matters. The document is a registration prospectus for securities resale, not a financial report, earnings release, or management discussion. It is a capital markets document related to financing activities and share registration for resale. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full prospectus, not just an announcement. Hence, the classification is CAP with high confidence.
2026-02-11 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.